T1	Participants 464 518	patients with hormone-receptor-positive breast cancer.
T2	Participants 602 743	postmenopausal women with hormone-receptor-positive, locally advanced or metastatic breast cancer previously treated with endocrine treatment
T3	Participants 1449 1535	189 patients and enrolled 156 (106 in the ganitumab group and 50 in the placebo group)
T4	Participants 2501 2601	women with previously treated hormone-receptor-positive locally advanced or metastatic breast cancer
